{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:09:24Z","timestamp":1790770164893,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,6,9]],"date-time":"2008-06-09T00:00:00Z","timestamp":1212969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Patients with relapsed or refractory MCL were eligible to receive temsirolimus 25 mg intravenously every week as a single agent. Patients who had a tumor response after 6 cycles were eligible to continue drug for a total of 12 cycles or 2 cycles after complete remission and then were observed without maintenance.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Of 29 enrolled patients, 28 were evaluable for toxicity, and 27 were evaluable for efficacy. The median age was 69 years (range, 51\u201385 years), 86% of patients had stage IV disease, and 71% had \u22652 extranodal sites. Patients had received a median of 4 prior therapies (range, 1\u20139 prior therapies), and 50% were refractory to the last treatment. The overall confirmed response rate was 41% (11 of 27 patients; 90% confidence interval [CI], 22%\u201361%) with 1 complete response (3.7%) and 10 partial responses (37%). The median time to progression in all eligible patients was 6 months (95% CI, 3\u201311 months), and the median duration of response for the 11 responders was 6 months (range, 1\u201326 months). Hematologic toxicities were the most common, with 50% (14 of 28 patients) grade 3 and 4% (1 of 28 patients) grade 4 toxicities observed. Thrombocytopenia was the most frequent cause of dose reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>Single\u2010agent temsirolimus at a dose of 25 mg weekly is an effective new agent for the treatment of MCL. The 25\u2010mg dose level retained the antitumor activity of the 250\u2010mg dose with less myelosuppression. Further studies of temsirolimus in combination with other active drugs for MCL and other lymphoid malignancies are warranted. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23580","type":"journal-article","created":{"date-parts":[[2008,6,9]],"date-time":"2008-06-09T18:16:30Z","timestamp":1213035390000},"page":"508-514","source":"Crossref","is-referenced-by-count":184,"title":["Low\u2010dose, single\u2010agent temsirolimus for relapsed mantle cell lymphoma"],"prefix":"10.1002","volume":"113","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Kendrith M.","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roscoe F.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Dennis F.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Allmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,9]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_5_3_2","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-006-0038-1"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.185"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404471"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.121.121"},{"issue":"18","key":"e_1_2_5_13_2","article-title":"A phase III, randomized, 3\u2010arm study of temsirolimus (TEMSR) or interferon\u2010alpha (IFN) or the combination of TEMSR + IFN in the treatment of first\u2010line, poor\u2010risk patients with advanced renal cell carcinoma (adv RCC)","volume":"24","author":"Hudes G","year":"2006","journal-title":"J Clin Oncol 2006 ASCO Annual Meeting Proceedings."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl316"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0871"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1091"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.531.531","article-title":"Preliminary results from a phase II study of lenalidomide monotherapy in relapsed\/refractory aggressive non\u2010Hodgkins lymphoma","volume":"108","author":"Wiernik PH","year":"2006","journal-title":"Blood."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701361828"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819042000223822"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0023-2"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23580","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:11:56Z","timestamp":1760263916000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23580"}},"subtitle":["A phase 2 trial in the North Central Cancer Treatment Group"],"short-title":[],"issued":{"date-parts":[[2008,6,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1002\/cncr.23580"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23580","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,9]]}}}